問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chung Shan Medical University Hospital (在職)

Division of General Internal Medicine

Division of Endocrinology

更新時間：2023-09-19

黃建寧
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

9Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃建寧

Chung Shan Medical University Hospital

Division of Endocrinology

List

46Cases

2010-03-03 - 2010-12-31

Phase III

A pan-Asian clinical trial comparing the efficacy and safety of insulin NN1250 and insulin glargin in patients with type 2 diabetes who are currently using oral hypoglycemic drugs. A 26-week, randomized, confirmatory, controlled, open-ended, multi-center, multi-country, clinical trial that achieves the treatment goals, comparing SIBA and insulin glargine injected once a day with oral hypoglycemic drugs for type 2 diabetes The efficacy and safety of patients.

  • Condition/Disease

    Diabetes

  • Test Drug

    Insulin 454 (SIBA) 100 U/ml, 3 mL prefilled pen, solution for injection

Participate Sites
8Sites

Terminated8Sites

2015-09-01 - 2017-04-04

Phase III

A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 Diabetes Mellitus (EASE2)

  • Condition/Disease

    Type 1 Diabetes Mellitus

  • Test Drug

    Jardiance®

Participate Sites
8Sites

Terminated7Sites

陳清助
China Medical University Hospital-Taipei

未分科

2012-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2010-09-01 - 2012-07-01

Phase III

A phase III randomized, double-blind, placebo-controlled, parallel trial to evaluate BI 10773 (10 mg, 25 mg) orally once a day for a 24 week course of treatment after treatment with Metformin or combined Metformin and Sulfonylurea Efficacy and safety of type 2 diabetes patients with poor blood glucose control

  • Condition/Disease

    Type 2 or unspecified diabetes

  • Test Drug

    BI 10773

Participate Sites
9Sites

Terminated9Sites

2011-05-01 - 2013-06-30

Phase III

A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (incl. 24 weeks of preceding trial) as monotherapy or with different back-ground therapies in patients with type 2 diabetes mellitus previously completing trial 1245.19, 1245,20 or 1245.23.

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    BI 10773

Participate Sites
9Sites

Terminated9Sites

2006-04-01 - 2008-10-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated1Sites

Study ended4Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB